Amylyx Pharmaceuticals, Inc. Income Statement

Income Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 2.94M0.28M27.10M431.43M114.27M
Cost of Revenue 2.99M25.44M5.95M
Gross Profit 24.11M405.99M108.31M
Operating items
Research & Development 24.59M44.04M93.45M128.19M104.08M
Selling, General & Administrative 15.06M38.93M127.13M188.36M114.33M
Restructuring Costs 22.85M
Other Operating Expenses 2.99M25.44M160.84M
Operating Expenses 39.66M82.97M223.57M341.98M402.10M
Operating Income -39.01M-82.69M-201.34M38.80M-314.73M
EBIT -39.01M-82.69M-201.34M38.80M-314.73M
Non-operating items
Interest & Investment Income 0.01M0.04M4.29M16.16M13.81M
Other Non Operating Income -3.27M-0.05M-0.55M-0.66M-1.21M
Non Operating Income -5.24M3.74M15.49M12.60M
Net income details
EBT -36.70M-87.93M-198.70M54.30M-302.14M
Tax Provisions 0.77M5.25M-0.77M
Profit After Tax -42.28M-87.93M-198.38M49.27M-301.74M
Investment Income 0.01M
Income from Continuing Operations -36.70M-87.93M-199.48M49.05M-301.37M
Consolidated Net Income -36.70M-87.93M-199.48M49.05M-301.37M
Income towards Parent Company -36.70M-87.93M-199.48M49.05M-301.37M
Net Income towards Common Stockholders -36.70M-87.93M-199.48M49.05M-301.37M
Additional items
EPS (Basic) -0.66-13.35-3.390.73-4.43
EPS (Weighted Average and Diluted) -13.35-3.390.70-4.43
Shares Outstanding (Weighted Average) 55.22M57.86M66.26M67.52M68.55M
Shares Outstanding (Diluted Average) 6.59M58.50M69.99M
EBITDA -39.01M-82.69M-201.34M38.80M-314.73M
Interest Expenses -2.29M
Tax Rate 9.67%0.25%